"Pharma R&D programme to provide sustained incentives for investment": Bayer Zydus

01 February 2023 | Views

Manoj Saxena, Managing Director, Bayer Zydus Pharma shares his reactions on Union Budget 2023-24

“A new programme to promote pharmaceutical research & development (R&D) will help spur investment in innovations that can address areas of high disease burden and unmet health needs in India. This is a long-awaited move, and we hope such a programme will provide sustained incentives for investment so that the Indian pharmaceutical industry becomes a global hub for both discovery and development work.

Another critical requirement in India’s journey to provide healthcare for all has been to augment health system resources and medical personnel. The move to introduce 157 new nursing colleges in co-location with existing medical colleges will help relieve pressures on doctors and in the long term, increase health system capacity. This will facilitate greater and faster access to primary and preventive healthcare.”